Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Flavopiridol, Fludarabine, and Rituximab in Treating Patients With Lymphoproliferative Disorders or Mantle Cell Lymphoma
This study has been completed.
Study NCT00058227 Information provided by National Cancer Institute (NCI)
First Received: April 7, 2003 Last Updated: March 5, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Leukemia
Lymphoma
Additional conditions recognized in this trial
Lymphoma, Mantle-Cell
Lymphoproliferative Disorders
More general conditions related to this trial
Immune System Diseases
Immunoproliferative Disorders
Lymphatic Diseases
Lymphoma, Non-Hodgkin
Neoplasms
Neoplasms by Histologic Type
Interventions listed in this trial
rituximab
alvocidib
fludarabine phosphate
Additional drug interventions recognized in this trial
Flavopiridol
Fludarabine
Fludarabine monophosphate
More general drug interventions related to this trial
Antimetabolites
Antimetabolites, Antineoplastic
Antineoplastic Agents
Antirheumatic Agents
Enzyme Inhibitors
Growth Inhibitors
Growth Substances
Immunologic Factors
Immunosuppressive Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs
Protein Kinase Inhibitors
Therapeutic Uses
Sponsors listed in this trial
Arthur G. James Cancer Hospital &Richard J. Solove Research Institute
National Cancer Institute (NCI)
Back to top of Main Content
